{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:50:59Z","timestamp":1790470259710,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk of primary treatment failure versus RAI alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      ASTRA (ClinicalTrials.gov identifier: NCT01843062 ) is an international, phase III, randomized, placebo-controlled, double-blind trial. Patients with DTC at high risk of primary treatment failure (primary tumor &gt; 4 cm; gross extrathyroidal extension outside the thyroid gland [T4 disease]; or N1a\/N1b disease with \u2265 1 metastatic lymph node(s) \u2265 1 cm or \u2265 5 lymph nodes [any size]) were randomly assigned 2:1 to selumetinib 75 mg orally twice daily or placebo for approximately 5 weeks (no stratification). On treatment days 29-31, recombinant human thyroid-stimulating hormone (0.9 mg)\u2013stimulated RAI (\n                      <jats:sup>131<\/jats:sup>\n                      I; 100 mCi\/3.7 GBq) was administered, followed by 5 days of selumetinib\/placebo. The primary end point (CR rate 18 months after RAI) was assessed in the intention-to-treat population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Four hundred patients were enrolled (August 27, 2013-March 23, 2016) and 233 randomly assigned (selumetinib, n = 155 [67%]; placebo, n = 78 [33%]). No statistically significant difference in CR rate 18 months after RAI was observed (selumetinib n = 62 [40%]; placebo n = 30 [38%]; odds ratio 1.07 [95% CI, 0.61 to 1.87]; P = .8205). Treatment-related grade \u2265 3 adverse events were reported in 25\/154 patients (16%) with selumetinib and none with placebo. The most common adverse event with selumetinib was dermatitis acneiform (n = 11 [7%]). No treatment-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Postoperative pathologic risk stratification identified patients with DTC at high risk of primary treatment failure, although the addition of selumetinib to adjuvant RAI failed to improve the CR rate for these patients. Future strategies should focus on tumor genotype\u2013tailored drug selection and maintaining drug dosing to optimize RAI efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.21.00714","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T15:59:28Z","timestamp":1645545568000},"page":"1870-1878","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":69,"title":["Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)"],"prefix":"10.1200","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3742","authenticated-orcid":false,"given":"Alan L.","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill-Cornell New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-8219","authenticated-orcid":false,"given":"Marek","family":"Dedecjus","sequence":"additional","affiliation":[{"name":"Maria Sk\u0142odowska-Curie Institute, Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William B.","family":"Inabnet","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Kentucky College of Medicine, Lexington, KY"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tennvall","sequence":"additional","affiliation":[{"name":"Lund University and Sk\u00e5ne University Hospital, Department of Clinical Sciences, Oncology, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-7108","authenticated-orcid":false,"given":"Fernanda","family":"Vaisman","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[{"name":"Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Gianoukakis","sequence":"additional","affiliation":[{"name":"The Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, CA"},{"name":"David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire d\u2019Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Paschke","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-152X","authenticated-orcid":false,"given":"David","family":"Viola","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"So","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Carroll","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Hovey","sequence":"additional","affiliation":[{"name":"PHASTAR, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Thakre","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-2517","authenticated-orcid":false,"given":"James A.","family":"Fagin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ASTRA investigator group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0466"},{"key":"b3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"Tuttle RM","year":"2010","journal-title":"Thyroid"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04342.x"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.8.625"},{"key":"b6","volume-title":"NONMEM User\u2019s Guide","author":"Beal S","year":"2009"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206706"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"b9","first-page":"1454","volume":"63","author":"Kimura ET","year":"2003","journal-title":"Cancer Res"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2707"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0047"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46382"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1150"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2483"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1323-z"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209288"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00177"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0522"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1753"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00612"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01478"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89067"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0735"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.00714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T18:01:09Z","timestamp":1654624869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.00714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":24,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,6,10]]}},"alternative-id":["10.1200\/JCO.21.00714"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.00714","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"2021-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}